Cargando…
Phenotype distribution of the paraoxonase gene in patients with cardiac disease
INTRODUCTION: Paraoxonase (PON1) is an enigmatic enzyme with multiple enzymatic properties including arylesterase and lactonase activities besides its ability to hydrolyze the toxic metabolite of parathion, paraoxon. The aim of this study was to determine the phenotype distribution of PON1 in patien...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510503/ https://www.ncbi.nlm.nih.gov/pubmed/28721150 http://dx.doi.org/10.5114/aoms.2016.59674 |
_version_ | 1783250196044447744 |
---|---|
author | Ellidag, Hamit Yasar Aydin, Ozgur Eren, Esin Yilmaz, Necat Gencpinar, Tugra Kucukseymen, Selcuk Yilmaz, Akar Arslan Ince, Fatma Demet |
author_facet | Ellidag, Hamit Yasar Aydin, Ozgur Eren, Esin Yilmaz, Necat Gencpinar, Tugra Kucukseymen, Selcuk Yilmaz, Akar Arslan Ince, Fatma Demet |
author_sort | Ellidag, Hamit Yasar |
collection | PubMed |
description | INTRODUCTION: Paraoxonase (PON1) is an enigmatic enzyme with multiple enzymatic properties including arylesterase and lactonase activities besides its ability to hydrolyze the toxic metabolite of parathion, paraoxon. The aim of this study was to determine the phenotype distribution of PON1 in patients with cardiac disease who were classified in coronary artery bypass grafting (CABG), heart valve disease (HVD), heart failure (HF) and ST elevation myocardial infarction (STEMI) groups and healthy subjects as a control group. MATERIAL AND METHODS: A total of 300 people (100 cardiac surgery (70 CABG and 30 HVD), 70 HF, 30 STEMI patients and 100 healthy controls) were admitted to this study. Individual variations in PON1 were determined using the dual substrate (paraoxon and phenylacetate) method. RESULTS: The following phenotype distributions were found in the cardiac disease and control groups: cardiac disease group (n = 200): 48.5% (QQ), 42.5% (QR), 9% (RR) and control group (n = 100): 58% (QQ), 39% (QR), 3% (RR). RR (high activity) phenotypic distribution was more common in the cardiac disease group than in controls (p = 0.04). In particular, the frequency of the RR phenotype was two- to three-fold higher in the STEMI and HF patients compared to the controls as well as CABG and HVD groups. CONCLUSIONS: We found a higher percentage of RR phenotype in STEMI and HF patients compared to a large control group as well as compared to two other groups of cardiac disease patients. |
format | Online Article Text |
id | pubmed-5510503 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-55105032017-07-18 Phenotype distribution of the paraoxonase gene in patients with cardiac disease Ellidag, Hamit Yasar Aydin, Ozgur Eren, Esin Yilmaz, Necat Gencpinar, Tugra Kucukseymen, Selcuk Yilmaz, Akar Arslan Ince, Fatma Demet Arch Med Sci Clinical Research INTRODUCTION: Paraoxonase (PON1) is an enigmatic enzyme with multiple enzymatic properties including arylesterase and lactonase activities besides its ability to hydrolyze the toxic metabolite of parathion, paraoxon. The aim of this study was to determine the phenotype distribution of PON1 in patients with cardiac disease who were classified in coronary artery bypass grafting (CABG), heart valve disease (HVD), heart failure (HF) and ST elevation myocardial infarction (STEMI) groups and healthy subjects as a control group. MATERIAL AND METHODS: A total of 300 people (100 cardiac surgery (70 CABG and 30 HVD), 70 HF, 30 STEMI patients and 100 healthy controls) were admitted to this study. Individual variations in PON1 were determined using the dual substrate (paraoxon and phenylacetate) method. RESULTS: The following phenotype distributions were found in the cardiac disease and control groups: cardiac disease group (n = 200): 48.5% (QQ), 42.5% (QR), 9% (RR) and control group (n = 100): 58% (QQ), 39% (QR), 3% (RR). RR (high activity) phenotypic distribution was more common in the cardiac disease group than in controls (p = 0.04). In particular, the frequency of the RR phenotype was two- to three-fold higher in the STEMI and HF patients compared to the controls as well as CABG and HVD groups. CONCLUSIONS: We found a higher percentage of RR phenotype in STEMI and HF patients compared to a large control group as well as compared to two other groups of cardiac disease patients. Termedia Publishing House 2016-05-25 2017-06 /pmc/articles/PMC5510503/ /pubmed/28721150 http://dx.doi.org/10.5114/aoms.2016.59674 Text en Copyright: © 2016 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Clinical Research Ellidag, Hamit Yasar Aydin, Ozgur Eren, Esin Yilmaz, Necat Gencpinar, Tugra Kucukseymen, Selcuk Yilmaz, Akar Arslan Ince, Fatma Demet Phenotype distribution of the paraoxonase gene in patients with cardiac disease |
title | Phenotype distribution of the paraoxonase gene in patients with cardiac disease |
title_full | Phenotype distribution of the paraoxonase gene in patients with cardiac disease |
title_fullStr | Phenotype distribution of the paraoxonase gene in patients with cardiac disease |
title_full_unstemmed | Phenotype distribution of the paraoxonase gene in patients with cardiac disease |
title_short | Phenotype distribution of the paraoxonase gene in patients with cardiac disease |
title_sort | phenotype distribution of the paraoxonase gene in patients with cardiac disease |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510503/ https://www.ncbi.nlm.nih.gov/pubmed/28721150 http://dx.doi.org/10.5114/aoms.2016.59674 |
work_keys_str_mv | AT ellidaghamityasar phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease AT aydinozgur phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease AT erenesin phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease AT yilmaznecat phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease AT gencpinartugra phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease AT kucukseymenselcuk phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease AT yilmazakar phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease AT arslanincefatmademet phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease |